We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+15.22%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$349M
AUM Growth
+$70.6M
Cap. Flow
+$59.4M
Cap. Flow %
17.01%
Top 10 Hldgs %
68.99%
Holding
46
New
13
Increased
6
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$22.8M
2
DERM
Dermira, Inc.
DERM
+$22.1M
3
RXDX
Ignyta, Inc.
RXDX
+$19.6M
4
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$18.4M
5
ENTA icon
Enanta Pharmaceuticals
ENTA
+$14.1M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$23.4M
2
CMRX
Chimerix, Inc.
CMRX
+$6.64M
3
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$6.2M
4
VCEL icon
Vericel Corp
VCEL
+$5.35M
5
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$4.07M

Sector Composition

Rank Sector Weight
1 Healthcare 73.78%
2 Technology 2.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TENX icon
26
Tenax Therapeutics
TENX
$363M
$2.84M 0.81%
35
– –
FOMX
27
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.75M 0.5%
+274,756
New +$1.82M
ADVM
28
DELISTED
Adverum Biotechnologies
ADVM
$1.74M 0.5%
55,012
-74,530
-58% -$3.37M
ASND icon
29
Ascendis Pharma A/S
ASND
$16B
$1.01M 0.29%
+76,511
New +$1.18M
LSTA icon
30
Lisata Therapeutics
LSTA
$9.02M
$900K 0.26%
10,168
-1,236
-11% -$114K
PLXP
31
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$871K 0.25%
+10,989
New +$952K
VCEL icon
32
Vericel Corp
VCEL
$2.35B
$570K 0.16%
253,502
-1,857,236
-88% -$5.35M
PRTK
33
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$407K 0.12%
29,266
-276,193
-90% -$4.07M
SIOX
34
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$321K 0.09%
+3,125
New +$312K
RVNC
35
DELISTED
Revance Therapeutics, Inc.
RVNC
$295K 0.08%
+21,665
New +$383K
STRM
36
DELISTED
Streamline Health Solutions
STRM
$182K 0.05%
10,107
– –
RIGL icon
37
Rigel Pharmaceuticals
RIGL
$681M
$112K 0.03%
5,000
-10,787
-68% -$268K
ARDX icon
38
Ardelyx
ARDX
$1.22B
$30K 0.01%
+3,444
New +$28.1K
AMRN
39
Amarin Corp
AMRN
$298M
$4K ﹤0.01%
+100
New +$3.76K
ACAD icon
40
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-100,000
Closed -$2.8M
ATYR
41
aTyr Pharma
ATYR
$47.6M
– –
-3,565
Closed -$197K
CMRX
42
DELISTED
Chimerix, Inc.
CMRX
– –
-1,300,000
Closed -$6.64M
ICPT
43
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-100,000
Closed -$12.8M
FPRX
44
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-575,000
Closed -$23.4M
PTLA
45
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-29,300
Closed -$598K
PTLA
46
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-50,000
Closed -$1.02M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2016 Portfolio in Review

As of Q2 2016, Great Point Partners held 46 positions worth $349M, up 25% from $279M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Great Point Partners deployed $59.4M of net new capital in Q2 2016, opening 13 new positions and adding to 6 existing holdings. Its largest new stake was Eagle Pharmaceuticals, Inc.: 548,290 shares worth $21.3M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 69% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Tetraphase Pharmaceuticals, Inc., an estimated $6.2M trimmed.

  • Great Point Partners's largest Q2 2016 buy was Eagle Pharmaceuticals, Inc.: 548,290 shares worth $21.3M.
  • Great Point Partners added most to Ignyta, Inc. in Q2 2016, an estimated $19.6M increase.
  • Great Point Partners's biggest Q2 2016 reduction was Tetraphase Pharmaceuticals, Inc., cutting an estimated $6.2M.
  • Great Point Partners fully exited Five Prime Therapeutics, Inc. in Q2 2016, selling an estimated $23.4M.
  • Great Point Partners's ten largest holdings make up 69% of its $349M portfolio in Q2 2016.
  • Great Point Partners opened 13 new positions and closed 7 in Q2 2016.
  • Great Point Partners's portfolio value rose 25% quarter-over-quarter to $349M.

Based on Great Point Partners's 13F filing for Q2 2016, filed 15 Aug 2016.